← Back to patent-cliff list
Carvedilol sulfate
Tier C — Watch / tradeCarvedilol sulfate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：β-adrenoceptors, VDCCs, ADRA1
Indications (approved)：Traumatic brain injury, Heart failure, Essential hypertension
Regional status
US
-
EU
-
China
Discontinued
2014-01-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Carvedilol sulfate?
Approved indications include: Traumatic brain injury, Heart failure, Essential hypertension.
When does the Carvedilol sulfate patent expire?
No public expiry year is available for Carvedilol sulfate yet; this page updates once verified.
How do I get a quote for Carvedilol sulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01